Before joining Brandon Capital, Mara was co-founder and COO of CytoVale, a San Francisco based startup developing a diagnostic for early sepsis detection. At CytoVale Mara was instrumental in building the company from concept to clinical studies. Prior to this, Mara worked as a key member of an interdisciplinary team at Third Rock Ventures in the US, where she was focused on launching transformative life science companies, including Nurix and Decibel. Earlier, she worked with ClearView Healthcare Partners where she spearheaded commercial strategies and M&A due diligence on behalf of top 10 and speciality pharmaceutical clients across diverse therapeutic areas.
Mara is currently a director of Kimaritec.
Mara has a Bachelor of Science (Chemical Engineering) from University of Colorado Boulder and a PhD from the Harvard MIT Division of Health Sciences and Technology in Medical and Chemical Engineering. Mara is also a graduate of the Australian Institute of Company Directors (AICD).